دورية أكاديمية
أعرض في EDS

Evidence For Cannabidiol Modulation of Serotonergic Transmission in a Model of Osteoarthritis via in vivo PET Imaging and Behavioral Assessment.

التفاصيل البيبلوغرافية
العنوان: Evidence For Cannabidiol Modulation of Serotonergic Transmission in a Model of Osteoarthritis via in vivo PET Imaging and Behavioral Assessment.
المؤلفون: Ding YS; Radiology, New York University School of Medicine, New York, NY, USA.; Psychiatry, New York University School of Medicine, New York, NY, USA., Wang J; Radiology, New York University School of Medicine, New York, NY, USA., Kumar V; Radiology, New York University School of Medicine, New York, NY, USA., Ciaccio J; Chemistry, Fordham University, Bronx, NY, USA., Dakhel S; Chemistry, New York University, New York, NY, USA., Tan C; Chemistry, New York University, New York, NY, USA., Kim J; Chemistry, New York University, New York, NY, USA., Lee S; Radiology, New York University School of Medicine, New York, NY, USA., Katz-Lichtenstein H; Radiology, New York University School of Medicine, New York, NY, USA., Gironda Z; Radiology, New York University School of Medicine, New York, NY, USA., Mishkit O; Radiology, New York University School of Medicine, New York, NY, USA., Mroz J; Radiology, New York University School of Medicine, New York, NY, USA., Jackson R; Radiology, New York University School of Medicine, New York, NY, USA., Yoon G; Radiology, New York University School of Medicine, New York, NY, USA., Gamallo-Lana B; Rodent Behavioral Core, New York University School of Medicine, New York, NY, USA., Klores M; Rodent Behavioral Core, New York University School of Medicine, New York, NY, USA., Mar A; Rodent Behavioral Core, New York University School of Medicine, New York, NY, USA.
المصدر: International journal of innovative research in medical science [Int J Innov Res Med Sci] 2022 Jun; Vol. 7 (6), pp. 254-271. Date of Electronic Publication: 2022 Jun 03.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: International Journal of Innovative Research in Medical Science Country of Publication: India NLM ID: 101731694 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2455-8737 (Electronic) Linking ISSN: 24558737 NLM ISO Abbreviation: Int J Innov Res Med Sci Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Mandasaur : International Journal of Innovative Research in Medical Science
مستخلص: Background: Preclinical studies indicate that cannabidiol (CBD), the primary nonaddictive component of cannabis, has a wide range of reported pharmacological effects such as analgesic and anxiolytic actions; however, the exact mechanisms of action for these effects have not been examined in chronic osteoarthritis (OA). Similar to other chronic pain syndromes, OA pain can have a significant affective component characterized by mood changes. Serotonin (5-HT) is a neurotransmitter implicated in pain, depression, and anxiety. Pain is often in comorbidity with mood and anxiety disorders in patients with OA. Since primary actions of CBD are analgesic and anxiolytic, in this first in vivo positron emission tomography (PET) imaging study, we investigate the interaction of CBD with serotonin 5-HT 1A receptor via a combination of in vivo neuroimaging and behavioral studies in a well-validated OA animal model.
Methods: The first aim of this study was to evaluate the target involvement, including the evaluation of modulation by acute administration of CBD, or a specific target antagonist/agonist intervention, in control animals. The brain 5-HT 1A activity/availability was assessed via in vivo dynamic PET imaging (up to 60 min) using a selective 5-HT 1A radioligand ([ 18 F]MeFWAY). Tracer bindings of 17 ROIs were evaluated based on averaged SUVR values over the last 10 min using CB as the reference region. We subsequently examined the neurochemical and behavioral alterations in OA animals (induction with monosodium iodoacetate (MIA) injection), as compared to control animals, via neuroimaging and behavioral assessment. Further, we examined the effects of repeated low-dose CBD treatment on mechanical allodynia (von Frey tests) and anxiety-like (light/dark box tests, L/D), depressive-like (forced swim tests, FST) behaviors in OA animals, as compared to after vehicle treatment.
Results: The tracer binding was significantly reduced in control animals after an acute dose of CBD administered intravenously (1.0 mg/kg, i.v.), as compared to that for baseline. This binding specificity to 5-HT 1A was further confirmed by a similar reduction of tracer binding when a specific 5-HT 1A antagonist WAY1006235 was used (0.3 mg/kg, i.v.). Mice subjected to the MIA-induced OA for 13-20 days showed a decreased 5-HT 1A tracer binding (25% to 41%), consistent with the notion that 5-HT 1A plays a role in the modulation of pain in OA. Repeated treatment with CBD administered subcutaneously (5 mg/kg/day, s.c., for 16 days after OA induction) increased 5-HT 1A tracer binding, while no significant improvement was observed after vehicle. A trend of increased anxiety or depressive-like behavior in the light/dark box or forced swim tests after OA induction, and a decrease in those behaviors after repeated low-dose CBD treatment, are consistent with the anxiolytic action of CBD through 5HT 1A receptor activation. There appeared to be a sex difference: females seem to be less responsive at the baseline towards pain stimuli, while being more sensitive to CBD treatment.
Conclusion: This first in vivo PET imaging study in an OA animal model has provided evidence for the interaction of CBD with the serotonin 5-HT 1A receptor. Behavioral studies with more pharmacological interventions to support the target involvement are needed to further confirm these critical findings.
Competing Interests: Competing interests: The authors declare that they have no competing interests.
References: Br J Pharmacol. 2007 Mar;150(5):613-23. (PMID: 17245363)
Osteoarthritis Cartilage. 2008 Apr;16(4):415-22. (PMID: 18296075)
Pain. 2018 Oct;159(10):1932-1954. (PMID: 29847469)
PLoS One. 2011 Mar 15;6(3):e17752. (PMID: 21423614)
Clin Rheumatol. 2010 Nov;29(11):1277-83. (PMID: 20721594)
Behav Brain Res. 2006 Sep 25;172(2):294-8. (PMID: 16780966)
Neuroreport. 2002 Apr 16;13(5):567-70. (PMID: 11973447)
Biol Psychiatry. 2003 Nov 15;54(10):953-9. (PMID: 14625137)
J Rheumatol. 1997 Mar;24(3):555-9. (PMID: 9058665)
J Pain. 2016 Mar;17(3):374-82. (PMID: 26694132)
Handb Exp Pharmacol. 2005;(168):657-90. (PMID: 16596792)
J Exp Med. 2012 Jun 4;209(6):1121-34. (PMID: 22585736)
J Pain. 2008 Oct;9(10):883-91. (PMID: 18602869)
Psychopharmacology (Berl). 2017 Jul;234(14):2207-2217. (PMID: 28424834)
MMWR Morb Mortal Wkly Rep. 2018 Mar 30;67(12):349-358. (PMID: 29596405)
Neuroimage. 2013 Aug 15;77:125-32. (PMID: 23537936)
Front Pharmacol. 2019 May 03;10:468. (PMID: 31130863)
Neuropsychopharmacology. 2011 May;36(6):1219-26. (PMID: 21307846)
Environ Toxicol Pharmacol. 2019 Aug;70:103202. (PMID: 31173966)
Drug Metab Dispos. 1988 May-Jun;16(3):469-72. (PMID: 2900742)
Synapse. 2011 Jul;65(7):592-600. (PMID: 21484878)
Science. 1996 Nov 29;274(5292):1527-31. (PMID: 8929413)
Drug Alcohol Depend. 2017 Mar 01;172:9-13. (PMID: 28088032)
Synapse. 2013 Sep;67(9):596-608. (PMID: 23504990)
J Pharmacol Exp Ther. 2008 Jun;325(3):1007-15. (PMID: 18354058)
Arthritis Res Ther. 2017 May 25;19(1):106. (PMID: 28545594)
Drug Alcohol Depend. 2014 Nov 1;144:119-26. (PMID: 25220896)
Philos Trans R Soc Lond B Biol Sci. 2012 Dec 5;367(1607):3364-78. (PMID: 23108553)
J Clin Psychiatry. 1995 Oct;56(10):485-6. (PMID: 7559378)
J Rheumatol. 2000 Jun;27(6):1513-7. (PMID: 10852280)
Prog Neuropsychopharmacol Biol Psychiatry. 2006 Dec 30;30(8):1466-71. (PMID: 16876926)
J Labelled Comp Radiopharm. 2013 Oct;56(12):589-94. (PMID: 24285234)
Cochrane Database Syst Rev. 2006 Jan 25;(1):CD004257. (PMID: 16437479)
Br J Pain. 2017 Aug;11(3):119-133. (PMID: 28785408)
Eur J Pharmacol. 2012 Dec 15;697(1-3):158-64. (PMID: 23085269)
Psychopharmacology (Berl). 2012 Feb;219(3):859-73. (PMID: 21796370)
Neurosci Lett. 2009 Nov 13;465(2):184-8. (PMID: 19716399)
J Vis Exp. 2016 May 16;(111):. (PMID: 27214709)
Behav Brain Res. 2010 Feb 11;207(1):105-11. (PMID: 19800921)
Br J Pharmacol. 2014 Feb;171(3):636-45. (PMID: 24117398)
Psychopharmacology (Berl). 2004 Jul;174(2):254-9. (PMID: 14740147)
Anesth Analg. 2017 Nov;125(5):1638-1652. (PMID: 28537982)
Transplant Proc. 2018 Mar;50(2):461-464. (PMID: 29579828)
Eur J Pharmacol. 2005 Apr 11;512(2-3):199-205. (PMID: 15840405)
Ann Intern Med. 2015 Jan 6;162(1):46-54. (PMID: 25560713)
PLoS One. 2015 Apr 01;10(4):e0121342. (PMID: 25830772)
J Pharm Pharmacol. 2019 Jun;71(6):971-981. (PMID: 30784067)
Neurochem Res. 2005 Aug;30(8):1037-43. (PMID: 16258853)
Psychopharmacology (Berl). 1991;104(2):260-4. (PMID: 1678894)
Neuropsychopharmacology. 2004 Feb;29(2):417-26. (PMID: 14583744)
Mol Brain. 2018 Sep 17;11(1):51. (PMID: 30223868)
J Neurosci Methods. 1994 Jul;53(1):55-63. (PMID: 7990513)
Front Neuroanat. 2008 Apr 17;2:1. (PMID: 18958199)
Br J Pharmacol. 2007 Dec;152(7):1092-101. (PMID: 17876302)
Neuropsychopharmacology. 2006 Apr;31(4):795-803. (PMID: 16052245)
Arthritis Rheumatol. 2017 Jul;69(7):1429-1439. (PMID: 28380690)
Nucl Med Biol. 2007 Oct;34(7):865-77. (PMID: 17921037)
Br J Pharmacol. 2010 Jan;159(1):122-8. (PMID: 20002102)
Brain Res Bull. 2008 Mar 28;75(5):545-55. (PMID: 18355630)
PLoS One. 2015 Apr 27;10(4):e0127491. (PMID: 25915858)
Pain. 2000 Aug;87(2):149-158. (PMID: 10924808)
Psychoneuroendocrinology. 2015 Dec;62:389-91. (PMID: 26386543)
Br J Pharmacol. 2014 May;171(9):2426-39. (PMID: 24641282)
J Psychopharmacol. 1993 Jan;7(1 Suppl):82-8. (PMID: 22290374)
Neuropharmacology. 2016 Apr;103:16-26. (PMID: 26711860)
Rheumatology (Oxford). 2012 Nov;51(11):1931-41. (PMID: 22427408)
Ann Intern Med. 2017 Apr 4;166(7):514-530. (PMID: 28192789)
Pain. 2017 Dec;158(12):2442-2451. (PMID: 28885454)
Clin Rehabil. 2003 Feb;17(1):21-9. (PMID: 12617376)
Open Orthop J. 2012;6:558-63. (PMID: 23248728)
Addict Biol. 2015 Jan;20(1):43-55. (PMID: 23855434)
eNeuro. 2016 Dec 29;3(6):. (PMID: 28058270)
Pain. 2019 Jan;160(1):136-150. (PMID: 30157131)
N Engl J Med. 2017 May 25;376(21):2011-2020. (PMID: 28538134)
Psychopharmacology (Berl). 1982;76(3):245-50. (PMID: 6285406)
Nat Rev Rheumatol. 2014 Jun;10(6):374-80. (PMID: 24686507)
J Nucl Med. 2006 Oct;47(10):1697-706. (PMID: 17015907)
Osteoarthritis Cartilage. 2016 Nov;24(11):1837-1849. (PMID: 26995111)
J Neurosci. 2007 Oct 24;27(43):11700-11. (PMID: 17959812)
Depress Anxiety. 2000;12 Suppl 1:2-19. (PMID: 11098410)
Eur J Pain. 2011 Sep;15(8):843.e1-14. (PMID: 21315627)
Clin Exp Rheumatol. 2017 Sep-Oct;35 Suppl 107(5):79-84. (PMID: 28967359)
Neuroreport. 1994 Jul 21;5(12):1438-40. (PMID: 7948833)
Arthritis Rheum. 2008 Jan;58(1):26-35. (PMID: 18163497)
J Clin Pharmacol. 2002 Nov;42(S1):11S-19S. (PMID: 12412831)
Neuropsychopharmacology. 2011 Jun;36(7):1489-504. (PMID: 21430651)
Eur J Pain. 2020 Apr;24(4):783-790. (PMID: 31889375)
JAMA. 2015 Jun 23-30;313(24):2456-73. (PMID: 26103030)
Br J Pharmacol. 2004 Sep;143(2):247-50. (PMID: 15313881)
J Nucl Med. 2014 Dec;55(12):1973-9. (PMID: 25453045)
Neuropsychopharmacology. 2012 Jan;37(2):412-21. (PMID: 21918503)
Curr Protoc Neurosci. 2001 May;Chapter 8:Unit 8.10A. (PMID: 18428536)
J Arthroplasty. 2017 Dec;32(12):3578-3582.e1. (PMID: 28887019)
Osteoarthritis Cartilage. 2013 Sep;21(9):1236-42. (PMID: 23973136)
J Pain. 2012 Aug;13(8):715-24. (PMID: 22607834)
Br J Pharmacol. 2011 Feb;162(3):584-96. (PMID: 20942863)
Curr Pain Headache Rep. 2014 Oct;18(10):456. (PMID: 25160712)
MMWR Morb Mortal Wkly Rep. 2018 Sep 14;67(36):1001-1006. (PMID: 30212442)
Biol Sex Differ. 2013 Feb 04;4(1):4. (PMID: 23374401)
Psychopharmacology (Berl). 1990;100(4):558-9. (PMID: 1969666)
Arthritis Rheum. 2012 Jun;64(6):1697-707. (PMID: 22392533)
Pain. 2000 May;86(1-2):11-8. (PMID: 10779655)
Neuroimage. 2008 Feb 1;39(3):1408-19. (PMID: 18036835)
Eur J Pharmacol. 2007 Feb 5;556(1-3):75-83. (PMID: 17157290)
Br J Pharmacol. 2001 Oct;134(4):845-52. (PMID: 11606325)
Arthritis Rheum. 2007 Apr 15;57(3):415-22. (PMID: 17394226)
J Pain. 2015 Aug;16(8):769-80. (PMID: 26028573)
معلومات مُعتمدة: P41 EB017183 United States EB NIBIB NIH HHS; R21 AT010771 United States AT NCCIH NIH HHS
فهرسة مساهمة: Keywords: Anxiety; Cannabidiol; Osteoarthritis; PET imaging; Pain; Serotonin receptor
تواريخ الأحداث: Date Created: 20231016 Latest Revision: 20240210
رمز التحديث: 20240210
مُعرف محوري في PubMed: PMC10576525
DOI: 10.23958/ijirms/vol07-i06/1418
PMID: 37841504
قاعدة البيانات: MEDLINE
الوصف
تدمد:2455-8737
DOI:10.23958/ijirms/vol07-i06/1418